165 related articles for article (PubMed ID: 33770057)
21. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
23. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
[TBL] [Abstract][Full Text] [Related]
24. Expression of podoplanin in ovarian clear cell carcinoma.
Kotarski J; Marzec-Kotarska B; Szumiło J; Klepacz R; Cybulski M; Małgorzata S; Bednarek W
Ginekol Pol; 2011 May; 82(5):350-3. PubMed ID: 21851033
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
26. [Ovarian clear cell carcinoma derived from endometriotic cyst: a clinicopathological analysis of 54 cases].
Zhu Q; Lu Y; Rao Y; Ning Y; Qu Y; Wang L; Zhou X
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):838-42. PubMed ID: 26887772
[TBL] [Abstract][Full Text] [Related]
27. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
28. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
[TBL] [Abstract][Full Text] [Related]
29. Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study.
Tranoulis A; Buruiana FH; Gupta B; Kwong A; Lakhiani A; Yap J; Balega J; Singh K
Arch Gynecol Obstet; 2022 May; 305(5):1279-1289. PubMed ID: 34468823
[TBL] [Abstract][Full Text] [Related]
30. p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma.
Liu J; Wang H; Zheng M; Deng L; Zhang X; Lin B
Int J Mol Med; 2020 Dec; 46(6):2102-2114. PubMed ID: 33125094
[TBL] [Abstract][Full Text] [Related]
31. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
32. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
33. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
[TBL] [Abstract][Full Text] [Related]
34. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
35. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
36. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
[TBL] [Abstract][Full Text] [Related]
37. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
[TBL] [Abstract][Full Text] [Related]
38.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
[TBL] [Abstract][Full Text] [Related]
40. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
